Adelaide S Robb1, Robert L Findling2, Ann C Childress3, Sally A Berry4, Heidi W Belden4, Sharon B Wigal5. 1. 1 George Washington University, Washington, DC, USA. 2. 2 Johns Hopkins University, Baltimore, MD, USA. 3. 3 Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV, USA. 4. 4 Pfizer Inc., New York, NY, USA. 5. 5 AVIDA Inc, Newport Beach, CA, USA.
Abstract
OBJECTIVE: To test whether an optimal dose of Quillivant XR (methylphenidate extended-release oral suspension [MEROS]) would significantly reduce symptoms of ADHD in children. METHOD: A randomized, double-blind, placebo-controlled, cross-over, efficacy, safety, and tolerability study of MEROS in 45 children aged 6 to 12 years (open-label dose-optimization phase, followed by double-blind cross-over period). RESULTS: MEROS was significantly more efficacious than placebo during double-blind cross-over laboratory classroom days (Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale and Permanent Product Measure of Performance). During the open-label phase, improvements were observed in scores of ADHD Rating Scale-IV, and Clinical Global Impression-Severity and -Improvement Scales. No occurrences of suicidal ideation or behavior were recorded; the most common open-label treatment-emergent adverse events were typical of stimulant use: decreased appetite, insomnia, and abdominal pain. CONCLUSION: MEROS was efficacious in the treatment of children aged 6 to 12 years with ADHD, with a safety profile similar to that of other extended-release methylphenidate pharmacotherapies.
RCT Entities:
OBJECTIVE: To test whether an optimal dose of Quillivant XR (methylphenidate extended-release oral suspension [MEROS]) would significantly reduce symptoms of ADHD in children. METHOD: A randomized, double-blind, placebo-controlled, cross-over, efficacy, safety, and tolerability study of MEROS in 45 children aged 6 to 12 years (open-label dose-optimization phase, followed by double-blind cross-over period). RESULTS: MEROS was significantly more efficacious than placebo during double-blind cross-over laboratory classroom days (Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale and Permanent Product Measure of Performance). During the open-label phase, improvements were observed in scores of ADHD Rating Scale-IV, and Clinical Global Impression-Severity and -Improvement Scales. No occurrences of suicidal ideation or behavior were recorded; the most common open-label treatment-emergent adverse events were typical of stimulant use: decreased appetite, insomnia, and abdominal pain. CONCLUSION: MEROS was efficacious in the treatment of children aged 6 to 12 years with ADHD, with a safety profile similar to that of other extended-release methylphenidate pharmacotherapies.
Entities:
Keywords:
ADHD; laboratory school; math test; methylphenidate; randomized-controlled trial
Authors: Ronald Steingard; Sarper Taskiran; Daniel F Connor; John S Markowitz; Mark A Stein Journal: J Child Adolesc Psychopharmacol Date: 2019-04-30 Impact factor: 2.576
Authors: Daniele Caprioli; Bianca Jupp; Young T Hong; Stephen J Sawiak; Valentina Ferrari; Laura Wharton; David J Williamson; Carolyn McNabb; David Berry; Franklin I Aigbirhio; Trevor W Robbins; Tim D Fryer; Jeffrey W Dalley Journal: J Neurosci Date: 2015-03-04 Impact factor: 6.167
Authors: Ann C Childress; Matthew Brams; Andrew J Cutler; Scott H Kollins; Jo Northcutt; Americo Padilla; John M Turnbow Journal: J Child Adolesc Psychopharmacol Date: 2015-02-18 Impact factor: 2.576